GlassScriptPhysician profile
Firas Bannout
NPI 1912068768
$5,389.39
in general payments reported to CMS, 2019-2025
41 companies · $670 in 2025
The $670 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $1,369 · 2021: $567 · 2022: $662 · 2023: $846 · 2024: $895 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,411.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $837.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic USA, INC. | $821.65 | 2020 | |
| Lilly USA, LLC | $690.74 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $391.14 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $354.46 | 2019-2025 | |
| Amgen INC. | $352.17 | 2019-2023 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $297.05 | 2020-2025 | Farxiga, Airsupra |
| Abbvie INC. | $202.41 | 2021-2025 | Ubrelvy |
| Janssen Pharmaceuticals, INC | $146.66 | 2020-2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $138.51 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.32 | 2021-2024 | Glassia |
| Idorsia Pharmaceuticals US INC | $121.31 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.67 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $70.87 | 2021-2025 | Gvoke Hypopen |
| Dexcom, INC. | $64.16 | 2022-2024 | Dexcom G6 Transmitter |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firas Bannout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.